Cathepsin L inhibitor (Biofront Therapeutics/Capital Medical University/Beijing Tongren Hospital)

N/A

Report date: 2025/06/11 10:21:28
NME

Base Information

Drug NameCathepsin L inhibitor (Biofront Therapeutics/Capital Medical University/Beijing Tongren Hospital)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionCathepsin L inhibitors
TargetsCathepsin L
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBiofront Therapeutics (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiofront Therapeutics (Beijing) Co LtdCapital Medical UniversityBeijing Tongren Hospital, Cmu
Inactive CompaniesN/A
Active IndicationsDiabetic Nephropathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A